Evotec (ETR:EVT) has been given a €20.00 ($23.26) target price by stock analysts at Berenberg Bank in a research note issued to investors on Wednesday, Borsen Zeitung reports. The firm currently has a “neutral” rating on the stock. Berenberg Bank’s target price indicates a potential downside of 14.71% from the stock’s previous close.
Separately, Deutsche Bank set a €23.00 ($26.74) price objective on shares of Evotec and gave the stock a “neutral” rating in a research note on Wednesday, April 10th.
Evotec stock opened at €23.45 ($27.27) on Wednesday. Evotec has a 52 week low of €12.18 ($14.16) and a 52 week high of €25.83 ($30.03). The company has a debt-to-equity ratio of 26.94, a current ratio of 1.27 and a quick ratio of 1.18. The company has a market capitalization of $3.50 billion and a P/E ratio of 41.88.
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.
See Also: Cost of Capital
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.